Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Myriam HormiRudy BirsenMaya BelhadjTony HuynhLilia Cantero AguilarEric GrignanoLamya HaddaouiFrançois GuillonneauPatrick MayeuxMathilde HunaultJérome TamburiniOlivier KosmiderMichaela FontenayDidier BouscaryNicolas ChapuisPublished in: European journal of haematology (2020)
These results are therefore of great relevance for clinicians as they provide the rational for combining BCL-2 and MCL-1 inhibition in AML.